Raymond James analyst John Ransom initiated coverage of Health Catalyst with a Strong Buy rating and $46 price target. The analyst cites the company's "attractive operating model" offering 90% recurring revenues and gross margin expansion, along with its differentiated product offering and "highly-awarded" culture. In an industry shift to more "value-centric payments", Health Catalyst has generated over 1K in "measurable, sustainable improvements for providers", responding to data warehousing needs that meet the nuances of healthcare data, Ransom tells investors in his research note.